Onalespib
Onalespib is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | 2 | 2 | — | — | — | 2 | ||
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | — | 1 | — | — | — | 1 |
| Prostatic neoplasms | D011471 | C61 | 1 | 1 | — | — | — | 1 | |
| Mantle-cell lymphoma | D020522 | C83.1 | — | 1 | — | — | — | 1 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | — | 1 | — | — | — | 1 | |
| Large-cell lymphoma anaplastic | D017728 | C84.6 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | — | — | — | — | 4 |
| Triple negative breast neoplasms | D064726 | 3 | — | — | — | — | 3 | ||
| Neoplasms | D009369 | C80 | 2 | — | — | — | — | 2 | |
| Melanoma | D008545 | 1 | — | — | — | — | 1 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | 1 | — | — | — | — | 1 | ||
| Squamous cell carcinoma of head and neck | D000077195 | 1 | — | — | — | — | 1 | ||
| Squamous cell carcinoma | D002294 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ONALESPIB |
| INN | onalespib |
| Description | Onalespib is a member of the class of isoindoles that is isoindole in which the amino group has been acylated by a 2,4-dihydroxy-5-isopropylbenzoyl group and in which position 5 of the isoidole moiety has been substituted by a (4-methylpiperazin-1-yl)methyl group. A second-generation Hsp90 inhibitor. It has a role as a Hsp90 inhibitor and an antineoplastic agent. It is a member of resorcinols, a member of benzamides, a tertiary carboxamide, a member of isoindoles and a N-alkylpiperazine. |
| Classification | Small molecule |
| Drug class | heat shock protein inhibitors; narcotic agonists/antagonists (normorphine type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O |
Identifiers
| PDB | — |
| CAS-ID | 912999-49-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1214827 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06306 |
| UNII ID | Q7Y33N57ZZ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 267 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more